Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-218 (safusidenib) is a novel, selective, potent, oral mIDH1 inhibitor, which is investigated for the treatment of Grades 2 or 3 recurrent or progressive mutant isocitrate dehydrogenase 1 (mIDH1) glioma, one of the most common types of adult primary br...
Product Name : AB-218
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safusidenib (also known as AB-218), is a small molecule mIDH1 inhibitor. Mutations in IDH1 are frequently found in various tumor types such as glioma, cholangiocarcinoma, and chondrosarcoma. Safusidenib has also shown high blood brain barrier penetration...
Product Name : AB-218
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Safusidenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
